BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/10/2014 7:09:00 PM | Browse: 1480 | Download: 1103
Publication Name World Journal of Gastroenterology
Manuscript ID 6854
Country Japan
Received
2013-10-29 15:38
Peer-Review Started
2013-10-30 20:30
To Make the First Decision
2013-12-16 17:32
Return for Revision
2014-04-02 08:58
Revised
2014-04-07 20:27
Second Decision
2014-05-05 09:29
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-05 09:58
Articles in Press
2014-05-23 10:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-10-25 13:59
Publish the Manuscript Online
2014-11-10 19:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Topic Highlights
Article Title S-1 in the treatment of pancreatic cancer
Manuscript Source Invited Manuscript
All Author List Kentaro Sudo, Kazuyoshi Nakamura and Taketo Yamaguchi
Funding Agency and Grant Number
Corresponding Author Kentaro Sudo, MD, PhD, Department of Gastroenterology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan. kentarosudo9@yahoo.co.jp
Key Words Pancreatic cancer; S-1; Chemotherapy; Randomized controlled trial; Chemoradiotherapy; Adjuvant therapy
Core Tip This review article focuses on clinical trials of S-1-based chemotherapy for advanced pancreatic cancer. Recently, S-1 has been demonstrated to be non-inferior to gemcitabine in overall survival for metastatic or locally advanced pancreatic cancer in a large-scale phase Ⅲ study (GEST study). Furthermore, S-1 has been shown to be superior to adjuvant chemotherapy with gemcitabine in overall survival in patients with resected pancreatic cancer in another phase Ⅲ study (JASPAC-01 study). In addition to gemcitabine, S-1 is now considered one of the key drugs in Japan.
Publish Date 2014-11-10 19:10
Citation Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014; 20(41): 15110-15118
URL http://www.wjgnet.com/1007-9327/full/v20/i41/15110.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i41.15110
Full Article (PDF) WJG-20-15110.pdf
Full Article (Word) WJG-20-15110.doc
Manuscript File 6854-Review.doc
Answering Reviewers 6814-Answering reviewers.pdf
Copyright License Agreement 6814-Copyright assignment.pdf
Peer-review Report 6874-Peer reviewer(s).pdf
Scientific Editor Work List 6814-Scientific editor work list.doc